MiRNA-148b and Its Role in Various Cancers

Dorraki, Najmeh; Ghale-Noie, Zari Naderi; Ahmadi, Nooshin Sadegh; Keyvani, Vahideh; Bahadori, Rosita Azar; Nejad, Arash Salmani; Aschner, Michael; Pourghadamyari, Hossein; Mollazadeh, Samaneh; Mirzaei, Hamed

doi:10.2217/epi-2021-0155

Cited by 21 publications

(8 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 Instead, miR-148b exerts the opposite effect and acts as a tumour suppressor through regulating invasion-, apoptosis- and proliferation-related oncogenes. 14 A case-control study confirmed the NGS ability to detect hotspot mutations in the EBC of lung cancer patients. 15 Another case-control study reported an increase in NSCLC risk associated with overexpression of miR-21 and under expression of miR-486 in plasma and in the exhaled breath condensate (EBC), which would pave the way towards a more extensive use of these biomarkers acquired through a non-invasive method.…”

Section: Introductionmentioning

confidence: 71%

Next Generation Sequencing for miRNA Detection on the Exhaled Breath Condensate: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

Introduction: Exhaled breath condensate (EBC) sampling has been suggested as a less-invasive and cost-effective method to detect biological macromolecules, including miRNA. To explore the feasibility of its use as a biomarker of early effects of asbestos exposure, we conducted a preliminary test on male volunteers by comparing the miRNA profile in the EBC and the plasma using 2 different sequencing platforms. Methods: Six male volunteers, all retired and unexposed to dust or fumes, participated in the test. RNA was extracted from 200 μL EBC samples and same-size plasma samples. Sample aliquots were processed in 2 laboratories using 2 different sequencing platforms: a MiSeq Illumina® platform and a more performing HiSeq Illumina® platform. Results: The HiSeq3000® sequencing platform identified twice as many unique molecular indexes (UMI)-validated miRNA as the MiSeq® platform. The Spearman’s correlation coefficient between EBC counts and plasma counts was significant in 5/6 subjects with either platform (MiSeq® = 0.128-0.508, P = .026-<.001; HiSeq® = 0.156-0.412, P = .001-<.001). The intraclass correlation coefficient confirmed the consistency of the miRNA profile over the 6 participants with both biospecimens. Exploring the agreement between the EBC and plasma samples with Bland-Altman plots showed that using the HiSeq3000® platform substantially improved the EBC miRNA detection rate. Conclusion: Our preliminary study confirms that, when using the HiSeq® sequencing platform, EBC sampling is a suitable, non-invasive method to detect the miRNA profile in healthy subjects.

show abstract

Section: Introductionmentioning

confidence: 71%

Next Generation Sequencing for miRNA Detection on the Exhaled Breath Condensate: A Pilot Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…These observations suggest that CAND1 might mediate invasion and metastasis in ERα-positive breast cancer, possibly through the stabilization of PLK4. In addition, CAND1 might mediate metastasis through the interaction with miR-148b-3p, which has been implicated in mediating the migration of breast cancer cell lines [ 20 , 21 ]; however, the exact mechanism remains to be unidentified.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, targeting CAND1 with miR-148b-3p regulates Schwann cells migration [ 19 ]. miR-148b-3p has also been implicated in mediating the proliferation and migration of breast cancer cell lines [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics Analysis of the Prognostic Significance of CAND1 in ERα-Positive Breast Cancer

Alhammad

2022

Diagnostics

View full text Add to dashboard Cite

The identification of novel prognostic biomarkers for breast cancer is an unmet clinical need. Cullin-associated and neddylation-dissociated 1 (CAND1) has been implicated in mediating carcinogenesis in prostate and lung cancers. In addition, CAND1 is an established prognostic biomarker for worse prognosis in liver cancer. However, the prognostic significance of CAND1 in breast cancer has not yet been explored. In this study, Breast Cancer Gene-Expression Miner (Bc-GenExMiner) and TIMER2.0 were utilized to explore the mRNA expression of CAND1 in ERα-positive breast cancer patients. The Kaplan–Meier plotter was used to explore the relationship between CAND1 expression and several prognostic indicators. The Gene Set Cancer Analysis (GSCA) web server was then used to explore the pathways of the genes that correlate with CAND1 in ERα-positive breast cancer. Immune infiltration was investigated using Bc-GenExMiner. Our bioinformatics analysis illustrates that breast cancer patients have higher CAND1 compared to normal breast tissue and that ERα-positive breast cancer patients with a high expression of CAND1 have poor overall survival (OS), distant metastasis-free survival (DMFS), and relapse-free survival (RFS) outcomes. Higher CAND1 expression was observed in histologic grade 3 compared to grades 2 and 1. Our results revealed that CAND1 positively correlates with lymph nodes and negatively correlates with the infiltration of immune cells, which is in agreement with published reports. Our findings suggest that CAND1 might mediate invasion and metastasis in ERα-positive breast cancer, possibly through the activation of estrogen and androgen signaling pathways; however, experiments should be carried out to further explore the role of CAND1 in activating the androgen and estrogen signaling pathways. In conclusion, the results suggest that CAND1 could be used as a potential novel biomarker for worse prognosis in ERα-positive breast cancer.

show abstract

“…binding to mRNAs and thereby promoting degradation of the target mRNA or blocking its translation into protein (19,(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79).…”

Section: N2bmentioning

confidence: 99%

Non-Coding RNAs and Oral Cancer: Small Molecules With Big Functions

2022

View full text Add to dashboard Cite

Oral cancer remains a major public concern with considerable socioeconomic impact in the world. Despite substantial advancements have been made in treating oral cancer, the five-year survival rate for oral cancer remained undesirable, and the molecular mechanisms underlying OSCC carcinogenesis have not been fully understood. Noncoding RNAs (ncRNAs) include transfer RNAs (tRNAs), as well as small RNAs such as microRNAs, and the long ncRNAs such as HOTAIR are a large segment of the transcriptome that do not have apparent protein-coding roles, but they have been verified to play important roles in diverse biological processes, including cancer cell development. Cell death, such as apoptosis, necrosis, and autophagy, plays a vital role in the progression of cancer. A better understanding of the regulatory relationships between ncRNAs and these various types of cancer cell death is therefore urgently required. The occurrence and development of oral cancer can be controlled by increasing or decreasing the expression of ncRNAs, a method which confers broad prospects for oral cancer treatment. Therefore, it is urgent for us to understand the influence of ncRNAs on the development of different modes of oral tumor death, and to evaluate whether ncRNAs have the potential to be used as biological targets for inducing cell death and recurrence of chemotherapy. The purpose of this review is to describe the impact of ncRNAs on cell apoptosis and autophagy in oral cancer in order to explore potential targets for oral cancer therapy.

show abstract

MiRNA-148b and Its Role in Various Cancers

Cited by 21 publications

References 149 publications

Next Generation Sequencing for miRNA Detection on the Exhaled Breath Condensate: A Pilot Study

Next Generation Sequencing for miRNA Detection on the Exhaled Breath Condensate: A Pilot Study

Bioinformatics Analysis of the Prognostic Significance of CAND1 in ERα-Positive Breast Cancer

Non-Coding RNAs and Oral Cancer: Small Molecules With Big Functions

Contact Info

Product

Resources

About